Lung Cancer Clinical Trials

Showing 961-980 of 3,692 trials

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

NCT06419179

Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)

Small Cell Lung Carcinoma

University of Cologne29 participantsStarted Oct 2024

Cologne, North Rhine-Westphalia, Germany

RECRUITINGPhase 3

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

NCT06123754

This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects with resectable stage IIIA and IIIB (N2) NSCLC. Primary study endpoints are MPR rate assessed by BIPR and EFS assessed by BIRC.

Non-small Cell Lung Cancer

3D Medicines (Sichuan) Co., Ltd.390 participantsStarted Nov 2023

Tianjin, Tianjin Municipality, China

RECRUITINGPhase 2

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

NCT06659042

The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.

Lung Cancer, Non-Small Cell

Shanghai Chest Hospital32 participantsStarted Nov 2024

Shanghai, Shanghai Municipality, China

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Related Searches

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

TGRX-326 Pharmacokinetic Food Effect Bioavailability Study

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Automated Device for Asthma Monitoring and Management in Monitoring Adults With Lung Cancer Undergoing Radiation Therapy

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Pre-habilitation in Lung Surgery Candidates

Definitive Radiation for High-Risk Spine Metastases

Navigation Endobronchial Ultrasound

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners

Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy